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Abstract
Background and purpose: The outcomes and management of colorectal cancer (CRC) hepatic metastasis have
undergone many evolutionary changes. In this study, we aimed to analyze the outcomes of patients with CRC
hepatic metastasis in terms of the era of treatment.
Methods: We conducted a retrospective review of 279 patients who underwent liver resection (LR) for CRC
hepatic metastases. The prognoses of patients treated pre-2003 (era 1) and post-2003 (era 2) were examined.
Results: Of the patients included in the study, 210 (75.3%) had CRC recurrence after LR. There was a significant
difference in the ratio of CRC recurrence between the 2 eras (82.0% in era 1 vs. 69.5% in era 2; p = 0.008). Analysis of
recurrence-free and overall survival rates also showed that the patient outcome was significantly better in the post-2003
era than in the pre-2003 era. Further analysis showed that a significantly higher percentage of patients in era 2 had
received modern chemotherapeutic regimens including irinotecan and oxaliplatin, while patients in era 1 were mainly
administered fluorouracil and leucovorin for adjuvant chemotherapy. Among patients with CRC recurrence, a significant
ratio of those in era 2 underwent surgical resection for recurrent lesions, and these patients had a better survival curve
than did patients without resection (34.1% vs. 2.2% for 5-year survival; p < 0.0001).
Conclusion: The incidence of CRC recurrence after LR for hepatic metastasis remains very high. However, the
management and outcomes of patients with CRC hepatic metastasis have greatly improved with time, suggesting
that the current use of aggressive multimodality treatments including surgical resection combined with modern
chemotherapeutic regimens effectively prolongs the life expectancy of these patients.
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Background
Hepatic metastasis is the most common form of distant
spread of primary colorectal cancer (CRC) and occurs in
over 50% of patients with metastases. Aggressive liver
resection (LR), which provides the only curative treat-
ment, is believed to have improved the long-term out-
come of these patients [1-3]. Recently published studies
have shown that these patients have variable 5-year survi-
val rates ranging from 36% to 58% [4-8]. However,
despite the excellent results of aggressive treatment for
metastatic CRC, numerous patients still develop recur-
rence after LR for metastatic tumors.
Although the prognostic factors and scoring systems
that determine patient outcomes after LR are well estab-
lished,[4,9-11] most of the information regarding LR for
metastatic CRC is from Western countries. However, CRC
has become a common gastrointestinal malignancy and
subsequently ranked as a leading cancerous disease in Tai-
wan and other East Asian countries during recent years.
Thus, we gathered data and retrospectively reviewed our
experience of LR for patients with hepatic metastasis from
CRC. Additionally, since the treatment of metastatic CRC
has changed greatly over the last decade, the patient
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ment to evaluate the evolution of outcome over the years.
Materials and methods
Patients
This study included 279 patients with CRC hepatic metas-
tasis who underwent LR with curative intent between July
1988 and December 2008 at Chang Gung Memorial Hos-
pital Linkou Medical Center (Taoyuan, Taiwan). The data
in the medical records of these patients were retrospec-
tively reviewed and analyzed for clinical characteristics,
surgical management, and outcome upon approval of the
institutional review board. Hepatic metastasis of CRC was
confirmed for all patients by histological examination of
specimens derived from LR. There were 177 men and 102
women, and their median age at the time of LR was 61
years (range, 21-88 years). The patient cohort was divided
into 2 subgroups: the first 15-year period was defined as
pre-2003; era 1, n = 128), and the later 5-year period was
defined as post-2003; era 2, n = 151). The clinicopatholo-
gic features and outcomes of patients were compared
between the 2 groups.
LR for CRC hepatic metastases
Before surgery, all patients were thoroughly evaluated
with appropriate imaging studies, including computed
tomography (CT) of the abdominal and pelvic areas,
chest roentgenography, and/or chest CT, to determine
the clinical status of the CRC and hepatic metastasis.
Positron emission tomography (PET) or PET/CT was not
routinely performed, but were done for patients who had
undergone equivocal conventional imaging studies to
confirm advanced disease and, occasionally, to identify
potentially resectable lesions. Resectability with curative
intent required complete resection of all hepatic meta-
static lesions and preservation of a sufficient volume of
remnant liver. In particular, a patient with concurrent
unresectable extrahepatic metastases was considered
unsuitable for LR. LR was performed using either the sur-
gical clamp-crush technique or the Cavitron Ultrasonic
Surgical Aspirator (CUSA; Valleylab, Inc., Boulder, CO,
USA). Inflow vascular control was not routinely applied
during the transection of liver parenchyma. The extent of
LR was defined according to Couinaud’s classification of
liver segments.
Postoperative follow-up
After LR, patients were followed up and monitored for
tumor recurrence by physicale x a m i n a t i o n ,m e a s u r i n g
the serum carcinoembryonic antigen (CEA) levels, and
conducting abdominal ultrasonography 1 month after
surgery, and every 3 months thereafter. CT and/or mag-
netic resonance imaging of the chest, abdomen, and pel-
vis were performed at yearly intervals or whenever
cancer recurrence was suspected. A PET or PET/CT
scan was occasionally arranged for patients who under-
went equivocal conventional imaging studies and experi-
enced unexplained elevation of serum CEA levels after
2003. Perioperative chemotherapy mainly depended on
tumor characteristics indicating aggressive disease, avail-
ability of chemotherapeutic regimens, patient’sp h y s i c a l
condition, and affordability of the chemotherapy drugs.
Usually, postoperative adjuvant chemotherapy was
recommended for all patients, unless a patient was
unwilling to receive chemotherapy or a patient’s physical
status was unsuitable for chemotherapy administration.
T h ec h e m o t h e r a p e u t i co p t i o n sw e r em o s t l yf l u o r o u r a c i l
and leucovorin before 2003 and a combination of new
options, including irinotecan, oxaliplatin, capecitabine,
bevacizumab, and cetuximab, after 2003. Pyrimidine
analogue capsules were prescribed for patients who had
not received intravenous chemotherapeutic regimens.
CRC recurrence was defined as the presence of a lesion
that was histologically proven from either biopsy or sur-
gical resection or the presence of a lesion that was
detected by cross-sectional imaging studies and/or con-
current with an elevation in serum CEA level. Intrahe-
patic recurrence (IHR) was defined as tumor recurrence
initially detected in the liver and no additional extrahe-
patic lesions detected within the following 3 months.
Systemic recurrence (SR) was defined as initial recur-
rence found outside the liver or both intra- and extrahe-
patic lesions simultaneously discovered or sequentially
detected within a 3-month period. Overall, 6 patients
were lost during the follow-up period, and the median
follow-up period for these patients was 25.5 months
(range, 4.0-240.1 months). The remaining patients were
followed up until death or the end of this study.
Statistical analysis
Statistical analyses were carried out using the statistical
software SPSS 13.0 (SPSS, Inc., Chicago, IL, USA) for
Windows. The outcome measures included recurrence-
free survival (RFS) and overall survival (OS). RFS was cal-
culated from the date of LR to the date of detected recur-
rence. The status of CRC recurrence was recorded at the
date of last follow-up for patients who were lost to fol-
low-up or died of other diseases, or the end of this study.
OS was measured from the date of LR to the date of
death. Categorical clinicopathologic features were
assessed with chi-square or Fisher’se x a c tt e s t .T h eC o x
regression proportional hazards model was used to iden-
tify factors influencing RFS, and all significant prognostic
factors determined in univariate analysis were then
selected for multivariate analysis. The survival curves
were constructed using the Kaplan-Meier method, and
the curves were compared using the log-rank test. A p
value of < 0.05 was defined as statistically significant.
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Demographics and clinicopathologic characteristics
The median follow-up period for the study patients was
27.2 months (range, 0.8-269.2 months). During follow-
up, 210 patients (75.3%) developed CRC recurrence, and
t h em e d i a nt i m eo fr e c u r r e n c ew a s9 . 0m o n t h s( r a n g e ,
1.1-129.8 months). Overall, at the end of this study, 191
patients (68.5%) had died, 26 (9.3%) were alive with CRC,
and 62 (22.2%) were alive without evidence of CRC.
Table 1 summarizes and compares the clinicopathologic
characteristics of the patients in era 1 and era 2. There
were significant differences in the age distribution, tumor
number, CRC recurrence, and perioperative chemother-
apy between the 2 groups. Patients in era 2 were older,
had a higher percentage of multiple hepatic metastases
(44.4% in era 2 vs. 24.2% in era 1; p < 0.001), had a lower
rate of CRC recurrence (69.5% vs. 82.0%; p = 0.008), and
received perioperative chemotherapeutic regimens differ-
ent from those in era 1 (p < 0.0001). Further detailed ana-
lysis regarding chemotherapies showed that a higher
percentage of patients in era 2 received fluorouracil and
leucovorin combined with irinotecan and oxaliplatin,
while patients of era 1 were mainly administered fluor-
ouracil and leucovorin for adjuvant chemotherapy. Nota-
bly, 8 (5.3%) patients who were initially considered
unsuitable for LR became eligible for surgical resection
after chemotherapy in era 2. There was no significant dif-
ference in the surgical mortality between the 2 groups.
Table 1 Clinicopathological characteristics of patients undergoing LR for hepatic metastasis from CRC in different eras.
Characteristics Era 1
n = 128 (%)
Era 2
n = 151 (%)
p value
Age in years, median (range) 59 (21-81) 63 (29-88) 0.009
Gender 0.194
Male 76 (59.4) 101 (66.9)
Female 52 (40.6) 50 (33.1)
Primary tumor location 0.112
Colon 65 (50.8) 91 (60.3)
Rectum 63 (49.2) 60 (39.7)
Liver metastasis
CEA (mg/dL), median (range) 15.5 (0.5-7025) 12.4 (0.8-4280) 0.743
Metastatic type 0.471
Synchronous 85 (66.4) 94 (62.3)
Metachronous 43 (33.6) 57 (37.7)
Tumor number < 0.0001
Solitary 97 (75.8) 84 (55.6)
Multiple 31 (24.2) 67 (44.4)
Maximum tumor size (cm) 0.331
< 5 108 (85.7) 122 (81.3)
≥5 20 (14.3) 29 (18.7)
Extent of liver resection 0.209
< 3 segments 88 (68.8) 114 (75.5)
≥ 3 segments 40 (31.2) 37 (24.5)
Perioperative chemotherapy < 0.0001
FU or with LV 69 (54.0) 8 (5.3)
FU/LV/oxaliplatin 9 (7.0) 36 (23.8)
FU/LV/irinotecan 9 (7.0) 67 (44.4)
Other regimens 22 (17.2) 30 (19.9)
No 19 (14.8) 10 (6.6)
CRC recurrence 0.008
IHR 57 (44.5) 43 (28.4)
SR 48 (37.5) 62 (41.1)
No 23 (18.0) 46 (30.5)
Resection of CRC recurrence 10 (9.5)* 31 (29.5)* 0.003
Surgical mortality 2 (1.6) 2 (1.3) 1.000
LR, liver resection; CRC, colorectal cancer; CEA, carcinoembryonic antigen; FU, fluorouracil; LV, leucovorin; IHR, intrahepatic recurrence; SR, systemic recurrence; *
represents percentage among CRC recurrence.
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Among the patients who developed CRC recurrence, 100
(47.6%) had IHR and 110 (52.4%) had SR according to the
classification of recurrence patterns. In era 1, 57 (44.5%)
patients had IHR and 48 (37.5%) patients had SR, while in
era 2, 43 (28.4%) patients had IHR and 62 (41.1%) patients
had SR. Table 2 provides an analysis of the risk factors for
CRC recurrence according to the different eras. Univariate
analysis showed that the type of hepatic metastases and
number of metastatic tumors were significant factors in
era 1. Subsequently, multivariate regression analysis of the
2 factors showed that multiple metastatic tumors (p =
0.035; hazard ratio [HR] = 1.6) was the sole independent
risk factor affecting CRC recurrence in era 1. In era 2, 4
factors, including the patient’s gender, type of hepatic
metastases, number of metastatic tumors, and width of
negative resection margin, were identified by univariate
analysis. Multivariate regression analysis of these factors
indicated that multiple metastatic tumors (p =0 . 0 1 7 ;
HR = 1.6) and resection margin < 0.5 cm (p =0 . 0 1 1 ;H R=
1.7) significantly influenced the recurrence of CRC in era
2. Further analysis of the clinical prognostic factors for all
patients showed that the presence of multiple metastatic
tumors and synchronous metastases were independent
risk factors affecting CRC recurrence (Table 3).
Outcomes after LR of hepatic metastasis
Overall, the 3-, 5-, and 10-year RFS rates were 24.0%,
21.1%, and 19.5%, respectively, and the 3-, 5-, and 10-year
OS rates were 41.3%, 32.1%, and 23.4%, respectively (Fig-
ure 1). Upon further analyses of the survival rates of
patients who received LR for hepatic metastasis according
Table 2 Univariate and multivariate analyses of clinicopathological factors affecting CRC recurrence of patients after
liver resection for hepatic metastases in different eras.
Factors Era 1 Era 2
Univariate Multivariate Univariate Multivariate
n Medium RFS months (95%CI) p value p value n Medium RFS months (95%CI) p value p value
Age (years)
< 65 89 8.0 (6.9-9.0) 0.296 - 84 12.0 (8.3-15.7) 0.300 -
≥65 39 12.0 (9.7-14.3) 67 21.0 (16.4-25.7)
Gender
Female 52 10.0 (8.1-11.9) 0.274 - 50 24.4 (11.7-37.1) 0.014 0.218
Male 76 9.0 (7.5-10.4) 101 14.5 (10.1-18.9)
Primary tumor
Colon 65 11.0 (8.9-13.0) 0.116 - 91 17.5 (10.4-24.6) 0.961 -
Rectum 63 8.0 (6.1-9.9) 60 16 (6.6-25.3)
Serum CEA (mg/dL)
≤200 83 11.0 (8.8-13.1) 0.550 - 115 17.5 (11.0-24.0) 0.362 -
> 200 38 9.0 (7.8-10.1) 94 15.3 (6.5-24.0)
Metastatic type
Synchronous 85 8.0 (6.8-9.2) 0.052 0.075 94 12.9 (8.5-17.3) 0.009 0.076
Metachronous 43 11.0 (8.8-13.1) 57 21.0 (7.4-34.7)
Tumor number
Solitary 97 10.0 (8.8-11.1) 0.022 0.035 84 22.1 (16.5-27.8) 0.001 0.028
Multiple 31 7.0 (5.3-8.7) 1.6 (1.0-2.5) 67 12.0 (10.6-13.5) 1.6 (1.1-2.4)
Maximum tumor size
< 5 cm 108 10.0 (8.8-11.2) 0.939 - 122 18.0 (12.6-23.5) 0.162 -
≥5 cm 20 8.0 (3.1-2.9) 29 11.9 (6.9-16.8)
Liver resection extent
< 3 segments 88 10.0 (8.5-11.4) 0.743 - 114 17.5 (11.1-23.9) 0.257 -
≥3 segments 40 9.0 (7.6-10.4) 37 13.0 (6.0-19.9)
Resection margin (cm)
< 0.5 60 9.0 (7.5-10.4) 0.773 - 87 12.0 (10.3-13.7) 0.001 0.011
≥0.5 68 10.0 (8.0-11.9) 64 23.3 (16.9-29.6) 1.7 (1.1-2.6)
Histology grade
Low grade 116 10.0 (8.8-11.2) 0.101 - 145 16.5 (11.0-22.0) 0.921 -
High grade 12 5.0 (2.1-7.9) 6 5.3 (0.0-30.4)
RFS, recurrence-free survival; CRC, colorectal cancer; CEA, carcinoembryonic antigen; CI, confidence interval
Chan et al. World Journal of Surgical Oncology 2011, 9:174
http://www.wjso.com/content/9/1/174
Page 4 of 10to the era in which they occurred, we found that the out-
come of patients in era 2 was significantly better than that
of patients in era 1 (Figure 2). Era 2 patients had better
RFS curves, and the 1-, 3-, and 5-year RFS rates were
55.6%, 28.2%, and 26.2%, respectively, with a median time
of CRC recurrence of 16.5 months. The 1-, 3-, and 5-year
RFS rates in era 1 patients were 35.1%, 19.1%, and 15.6%,
respectively, with a median time of CRC recurrence of
10.0 months (Figure 2A; p = 0.013). The 1-, 3-, and 5-year
OS rates of the patients in era 2 (89.3%, 56.5%, and 45.2%,
respectively, with a median survival of 44.6 months) were
better than those of patients in era 1 (77.2%, 25.2%, and
18.9%, respectively, with a median survival of 19 months)
(Figure 2B; p < 0.0001).
CRC recurrence after LR
The cumulative survival rates from the time of identifica-
tion of CRC recurrence after LR were further analyzed,
and patients with IHR and SR had poor survival curves.
Nonetheless, patients with IHR had a relatively better sur-
vival curve than patients with SR. The 3-year survival rates
were 14.5% in patients with IHR and 8.9% in patients with
SR (Figure 3A; p = 0.002). Of the 210 patients who devel-
oped CRC recurrence after LR, 41 (19.5%), including 24
with IHR and 17 with SR, underwent surgical resection for
the recurrent tumor. Of these patients, 31 (29.5%) had
CRC recurrence in era 2 and 10 (9.5%) had CRC recur-
rence in era 1. The comparison showed that the ratio
of patients who underwent surgical resection for CRC
recurrence was significantly higher in era 2 than in era 1
(Table 1; p = 0.003).
The survival rates according to whether or not patients
received surgical resection for recurrent CRC were further
analyzed. The results demonstrated that the outcome of
patients who underwent surgical resection (3- and 5-year
survivals of 46.8% and 34.1%, respectively) was significantly
Table 3 Univariate and multivariate analyses of clinicopathological factors affecting CRC recurrence in all patients
after liver resection for hepatic metastases
Factors Univariate analysis Multivariate analysis
n Medium RFS months (95% CI) p value p value (HR, 95% CI)
Age (years)
< 65 173 10.0 (8.4-11.6) 0.103 -
≥65 106 16.9 (9.9-24.0)
Gender
Male 177 12.0 (7.7-16.3) 0.021 0.134
Female 102 11.0 (9.0-13.0)
Primary tumor
Colon 156 12.9 (8.5-17.2) 0.234 -
Rectum 123 10.0 (8.5-11.5)
Serum CEA (mg/dL)
< 200 198 12.0 (10.6-13.4) 0.567 -
≥200 72 10.0 (7.3-12.7)
Metastatic type
Synchronous 179 10.8 (9.3-12.3) 0.002 0.014
Metachronous 100 15.0 (9.1-20.9) 1.5 (1.1-2.0)
Tumor number
Solitary 181 14.0 (8.9-19.1) 0.001 0.028
Multiple 98 10.0 (7.8-8.7) 1.4 (1.0-1.9)
Maximum tumor size
< 5 cm 230 12.0 (10.0-14.0) 0.420 -
≥5 cm 49 10.0 (6.9-13.1)
Extent of liver resection
< 3 segments 202 12.0 (9.3-14.7) 0.235 -
≥3 segments 77 10.0 (7.9-12.1)
Resection margin (cm)
< 0.5 147 10.0 (8.5-11.5) 0.019 0.073
≥0.5 132 14.5 (9.1-19.9)
Histologic grade
Low grade 261 12.0 (9.3-14.7) 0.184 -
high grade 18 5.3 (1.8-8.8)
RFS, recurrence free survival; CRC, colorectal cancer; CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio
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5-year survivals of 3.3% and 2.2%, respectively; Figure 3B; p
< 0.0001). The median follow-up period after surgical
resection for recurrent CRC for these patients was 22.7
months (range, 4.2-107.5 months). During the follow-up
period, 18 patients died of CRC relapse, 11 were still alive
with cancer, and the remaining 12 were alive and cancer-
free at the end of this study.
Discussion
Although CRC is a common malignancy worldwide, it
has only recently been ranked as a leading cancerous dis-
ease in East Asian countries. Therefore, the concept of
LR for CRC hepatic metastasis has started to receive con-
siderable attention in East Asian countries. In this study,
we have shown that the outcome of patients with CRC
hepatic metastasis who have undergone LR has notably
improved since 2003. The number of patients who have
undergone LR for CRC hepatic metastasis has also shown
a remarkable increase.
The overall recurrence incidence of 75.3% after LR for
CRC hepatic metastasis found in our study is slightly
higher than the recurrence rates reported by others
(range, 40-74%) [12-14]. However, our study evaluated
patients treated over a 20-year period, and treatment stra-
tegies for CRC hepatic metastasis have changed along with
advances in systemic therapy. As we had selected an arbi-
trary break point around the year 2003 on the basis of
access to modern chemotherapeutic regimens including
oxaliplatin and irinotecan at our institute, both the 5-year
RFS and the incidence of recurrence in era 2 were signifi-
cantly better than that in era 1. The percentage of patients
who received modern chemotherapeutic regimens was sig-
nificantly higher in era 2, suggesting that the use of cur-
rent chemotherapy is crucial for the improvement in
patient outcomes over the years. However, the regimens of
Figure 1 Long-term cumulative recurrence-free survival (RFS) and overall survival (OS) curves of patients undergoing liver resection
for hepatic metastasis from colorectal cancer.
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and comparison of patients grouped by different che-
motherapeutic regimens was not practical because of the
limited number of patients in each group. Therefore,
further information to clarify the effect of a specific
protocol in terms of postoperative adjuvant chemotherapy
regimens on patient outcomes is required.
A number of previous reports have shown several
prognostic factors that predict the outcome of patients
undergoing LR for CRC hepatic metastasis, and similar
A
B
Figure 2 Cumulative survival curves of patients who underwent liver resection for hepatic metastasis according to the era of their
treatment. A. The recurrence-free survival (RFS) rates in era 2 were significantly better than the RFS rates in era 1 (p = 0.013). B. The overall
survival (OS) rate in era 2 was better than the OS rate in era 1 (p < 0.0001).
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multiple hepatic metastases is the sole prognostic factor
influencing the risk of CRC recurrence in both eras, but
the width of the negative resection margin appeared to
be an additional risk factor during the recent era. The
data generated from this analysis cannot completely
explain the statistical differences. However, patients in
era 2 have higher ratios of multiple hepatic metastases
t h a nt h o s ei ne r a1 ,a n di ti ss o m e w h a td i f f i c u l tt o
achieve an adequate distance of negative resection
A
B
Figure 3 Kaplan-Meier cumulative survival curves of patients who underwent liver resection for hepatic metastasis after colorectal
cancer recurrence. A. The survival curve of patients with intrahepatic recurrence (IHR) was relatively better than that of patients with systemic
recurrence (SR) (p = 0.002). B. Patients who had undergone surgical resection of recurrent lesions had a better survival curve than did patients
without resection (p < 0.0001).
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maintain an adequate remnant liver volume, limited LR
or enucleation of multiple tumors might be performed,
and this might lead to inadequate safe resection mar-
gins. Therefore, the width of the negative resection mar-
gin as a prognostic factor might be explained, at least in
part, by aggressive LR for patients with multiple metas-
tases in era 2. Nonetheless, the advantages and disad-
vantages of adequate safe resection margins remain
controversial [15-18]. Despite the debate concerning the
width of a negative resection margin, there is consensus
that difficulty in obtaining an adequate resection margin
should not be used as an exclusion criterion for LR.
The concept of managing CRC hepatic metastasis by
surgical resection has greatly evolved in the last decade.
For example, the traditional indications of LR for CRC
hepatic metastases before the year 2000 were mainly lim-
ited to metastases confined to 1 lobe and/or less than
4 metastases,[19] which were not considered exclusion cri-
teria for LR afterward. The advancement in surgical tech-
niques and instruments used for LR has also decreased the
perioperative morbidity and mortality, leading to a more
aggressive approach of using LR for multiple hepatic
metastases from CRC over time. Confidence in the utility
of LR is also reflected in the increased age of patients in
era 2 than in era 1. Moreover, increasing evidence shows
that surgical resection of metastatic lesions with curative
intent has now become a standard practice for dealing
with several malignancies,[20-22] and the policy has been
expanded to include patients with recurrence after LR for
CRC metastasis. Although it remains arguable that the
prognosis of patients who are suitable to undergo surgical
resection is naturally better than that of patients who are
unable to undergo surgical resection, an aggressive atti-
tude with regard to surgical resection is indeed a benefit
to selected patients who have CRC hepatic metastasis or
recurrent CRC from LR for hepatic metastasis. Similar to
other recent studies,[23,24] we also found surgical resec-
tion of isolated recurrent lesions in selected patients to be
of advantage to those who have undergone LR for CRC
hepatic metastasis.
Conclusions
In summary, despite the study limitation imposed by the
relatively small number of patients and the retrospective
n a t u r e ,w es h o w e dt h a ta g g r e s s i v eL Rf o rC R Ch e p a t i c
metastasis and a combination of current chemotherapeutic
regimens led to improvements in the long-term outcome
of such patients. However, the ultimate aim is to establish
and standardize a promising treatment protocol that
involves the development of novel systemic chemotherapy
regimens for neoadjuvant and postoperative adjuvant
treatments, combined with aggressive surgical resection to
effectively prolong survival or even cure the patient of
CRC hepatic metastasis.
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